Last $0.77 USD
Change Today -0.02 / -2.53%
Volume 275.3K
NSPR On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 4:15 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

inspiremd inc (NSPR) Snapshot

Open
$0.80
Previous Close
$0.79
Day High
$0.85
Day Low
$0.75
52 Week High
02/26/14 - $3.80
52 Week Low
12/17/14 - $0.75
Market Cap
32.6M
Average Volume 10 Days
239.1K
EPS TTM
$-1.10
Shares Outstanding
42.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSPIREMD INC (NSPR)

Related News

No related news articles were found.

inspiremd inc (NSPR) Related Businessweek News

No Related Businessweek News Found

inspiremd inc (NSPR) Details

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MGuard stent platform technology. Its MGuard stent is an embolic protection device based on a protective sleeve, which is constructed out of an ultra-thin polymer mesh and wrapped around the stent. The company markets its products for use primarily in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack), and saphenous vein graft coronary interventions (bypass surgery). It serves various customers in Europe, Latin America, Asia, Israel, and internationally. InspireMD, Inc. is headquartered in Boston, Massachusetts.

71 Employees
Last Reported Date: 09/25/14

inspiremd inc (NSPR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Chief Financial Officer, Chief Administrative...
Total Annual Compensation: $142.3K
Chief Technology Officer, Chief Technical Off...
Total Annual Compensation: $136.3K
Compensation as of Fiscal Year 2013.

inspiremd inc (NSPR) Key Developments

InspireMD Announces Important Clinical Data from MASTER and CARENET Trials

InspireMD, Inc. announced results from two important clinical trials. 30 day results from the MASTER II trial which enrolled 310 of a planned 1,114 patients was presented at a major cardiology congress in Israel. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next generation MGuard drug eluting stent (DES) platform. The Company also announced ipsilateral DW-MRI results from the CARENET Trial for the CGuard system which successfully completed enrollment in July. MASTER II was a global clinical trial conducted under a U.S. Food and Drug Agency (FDA) Investigational Device Exemption (IDE) and was intended for U.S. registration of the MGuard Prime coronary EPS for use in patients presenting with STEMI (ST-segment Elevated Myocardial Infarction). The MASTER II trial was designed to show superiority of ST segment resolution 60-90 minutes post procedure as well non-inferiority in all-cause death or recurrent target vessel myocardial infarction. While the trial was halted well short of the planned enrollment, the Company elected to unblind the data and present the results on behalf of the study investigators.

InspireMD, Inc. Announces Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

InspireMD, Inc. announced consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's revenue decreased $1.3 million to $0.3 million compared to $1.6 million during the same period in 2013. The 2014 period included an expected decline in sales volume associated with the temporary stoppage of sales activities for the MGuard Prime EPS following the company's voluntary field action. Loss from operations was $6.5 million, an increase of 66.8% compared to $3.9 million for the same period in 2013. Net loss was $6.8 million, or $0.20 per basic and diluted share, compared to a net loss of $4.0 million, or $0.12 per basic and diluted share, in the same period in 2013. Non-GAAP net loss was $5.7 million, or $0.16 per basic and diluted share, an increase of 89.7% compared to a non-GAAP net loss of $3.0 million, or $0.09 per basic and diluted share, for the same period in 2013. Loss before tax expenses was $6.794 million against $3.942 million a year ago. For the nine months, the company’s revenue decreased $2.6 million to $1.9 million compared to $4.6 million during the same period in 2013. The 2014 period included a decline in sales volume associated with the temporary stoppage of sales activities for the MGuard Prime EPS following the company's VFA. Loss from operations was $19.3 million, an increase of 70.2%, compared to $11.3 million for the same period in 2013. Net loss was $20.3 million, or $0.59 per basic and diluted share, compared to a net loss of $23.8 million, or $0.86 per basic and diluted share, in the same period in 2013. Non-GAAP net loss was $17.1 million, or $0.50 per basic and diluted share, an increase of 107.7% compared to a non-GAAP net loss of $8.3 million, or $0.30 per basic and diluted share, for the same period in 2013. Loss before tax expenses was $20.302 million against $23.815 million a year ago.

InspireMD, Inc. to Report Q3, 2014 Results on Nov 12, 2014

InspireMD, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSPR:US $0.77 USD -0.02

NSPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.26 USD +0.86
Boston Scientific Corp $13.02 USD +0.07
Johnson & Johnson $104.07 USD +1.31
Medtronic Inc $72.67 USD +1.33
Sorin SpA €1.91 EUR +0.051
View Industry Companies
 

Industry Analysis

NSPR

Industry Average

Valuation NSPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSPIREMD INC, please visit www.inspire-md.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.